Eli Lilly's (LLY, Financial) weight loss drug, Zepbound, demonstrated superior results in a recent clinical trial compared to Novo Nordisk's Wegovy. Participants using Zepbound lost an average of 20% body weight over 72 weeks, outperforming Wegovy's 14% reduction. This result reinforces earlier findings of Zepbound's effectiveness, giving Eli Lilly a competitive edge in the obesity drug market, projected to reach $130 billion by the decade's end.
Following the trial results, Eli Lilly's stock rose 2.5%, while Novo Nordisk's fell 1.8%. Price competitiveness also plays a role, with Zepbound priced at $1,060 per month, lower than Wegovy's $1,349. The obesity drug market remains fiercely contested, with Novo Nordisk developing new treatments like CagriSema, aiming for further weight loss improvements.
